Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Rajan Website

Arun Rajan, M.D.

Selected Publications

1)  Tiseo M, Rajan A, Thomas A, Giaccone G.
"Pseudocavitation" in thymic carcinoma during treatment with sunitinib.
J Thorac Oncol. 8: 511-2, 2013.
2)  Thomas A, Mena E, Kurdziel K, Venzon D, Khozin S, Berman AW, Choyke P, Szabo E, Rajan A, Giaccone G.
18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors.
Clin. Cancer Res. 19: 1487-93, 2013.
3)  Kelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, Poondru S, Van Sant C, Keating A, Steinberg SM, Figg W, Giaccone G.
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
Ann. Oncol. 24: 2601-6, 2013.
4)  Thomas A, Xi L, Carter CA, Rajan A, Khozin S, Szabo E, Dennis PA, Giaccone G, Raffeld M.
Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations.
Clin Lung Cancer. 14: 452-6, 2013.
5)  Thomas A, Rajan A, Lopez-Chavez A, Wang Y, Giaccone G.
From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma.
Ann. Oncol. 24: 577-85, 2013.
6)  Petrini I, Rajan A, Pham T, Voeller D, Davis S, Gao J, Wang Y, Giaccone G.
Whole genome and transcriptome sequencing of a B3 thymoma.
PLoS ONE. 8: e60572, 2013.
7)  Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G.
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
Clin. Cancer Res. 18: 2344-51, 2012.
8)  Chowdhuri SR, Xi L, Pham TH, Hanson J, Rodriguez-Canales J, Berman A, Rajan A, Giaccone G, Emmert-Buck M, Raffeld M, Filie AC.
EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection.
Mod. Pathol. 25: 548-55, 2012.
9)  Khozin S, Roth MJ, Rajan A, Smith K, Thomas A, Berman A, Giaccone G.
Hepatoid carcinoma of the lung with anaplastic lymphoma kinase gene rearrangement.
J Thorac Oncol. 7: e29-31, 2012.
10)  Petrini P, French CA, Rajan A, Cameron MJ, Jaffe ES, Zucali PA, Xie J, Wang Y, Giaccone G.
NUT rearrangement is uncommon in human thymic epithelial tumors.
J Thorac Oncol. 7: 744-50, 2012.
11)  Komiya T, Thomas A, Khozin S, Rajan A, Wang Y, Giaccone G.
Response to crizotinib in ROS1-rearranged non-small-cell lung cancer.
J. Clin. Oncol. 30: 3425-6; author reply 3426, 2012.
12)  Thomas A, Rajan A, Giaccone G.
Tyrosine kinase inhibitors in lung cancer.
Hematol. Oncol. Clin. North Am. 26: 589-605, viii, 2012.
13)  Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, Gutierrez M, Crandon S, Zein WM, Jain L, Mannargudi B, Figg WD, Houk BE, Shnaidman M, Brega N, Giaccone G.
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
Clin. Cancer Res. 17: 6831-9, 2011.
14)  Gadalla SM, Rajan A, Pfeiffer R, Kristinsson SY, Björkholm M, Landgren O, Giaccone G.
A population-based assessment of mortality and morbidity patterns among patients with thymoma.
Int. J. Cancer. 128: 2688-94, 2011.
15)  Force J, Rajan A, Dombi E, Steinberg SM, Giaccone G.
Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.
J Thorac Oncol. 6: 1267-73, 2011.
16)  Rajan A, Giaccone G.
Chemotherapy for thymic tumors: induction, consolidation, palliation.
Thorac Surg Clin. 21: 107-14, viii, 2011.
17)  Kelly RJ, Rajan A, Force J, Lopez-Chavez A, Keen C, Cao L, Yu Y, Choyke P, Turkbey B, Raffeld M, Xi L, Steinberg SM, Wright JJ, Kummar S, Gutierrez M, Giaccone G.
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
Clin. Cancer Res. 17: 1190-9, 2011.
18)  Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A, Trepel J, Lee MJ, Cao L, Espinoza-Delgado I, Spittler J, Loehrer PJ.
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.
J. Clin. Oncol. 29: 2052-9, 2011.
19)  Kelly RJ, Petrini I, Rajan A, Wang Y, Giaccone G.
Thymic malignancies: from clinical management to targeted therapies.
J. Clin. Oncol. 29: 4820-7, 2011.
20)  Burbelo PD, Browne SK, Sampaio EP, Giaccone G, Zaman R, Kristosturyan E, Rajan A, Ding L, Ching KH, Berman A, Oliveira JB, Hsu AP, Klimavicz CM, Iadarola MJ, Holland SM.
Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia.
Blood. 116: 4848-58, 2010.
21)  Rajan A, Giaccone G.
Targeted therapy for advanced thymic tumors.
J Thorac Oncol. 5: S361-4, 2010.
22)  Kelly RJ, Browne SK, Rajan A, Giaccone G.
Thymoma-associated paraneoplastic polymyositis.
J. Clin. Oncol. 28: e378, 2010.
23)  Giaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C, Hogendoorn PC.
Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.
J Thorac Oncol. 4: 1270-3, 2009.
24)  Giaccone G, Rajan A.
Met amplification and HSP90 inhibitors.
Cell Cycle. 8: 2682, 2009.
25)  Carter CA, Rajan A, Giaccone G.
Plantar erythrodysesthesia with bullous otitis externa, toxicities from sorafenib: a case report.
Cases J. 2: 6264, 2009.
26)  Rajan A, Gutierrez M, Giaccone G.
Newer opportunities in systemic therapy of lung cancer.
Ann. Oncol. 19 Suppl 7: vii31-7, 2008.
27)  Rajan A, Giaccone G.
Treatment of advanced thymoma and thymic carcinoma.
Curr Treat Options Oncol. 9: 277-87, 2008.
Click Here to View Collapsed Bibliography.

This page was last updated on 12/13/2013.